BioSpace News Archive

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.

H-CYTE, Inc., a medical biosciences company focused on the field of regenerative medicine, announced that it has named Michael Yurkowsky as its Chief Executive Officer effective immediately.

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate NGM707, NGM’s wholly-owned novel ILT2/ILT4 dual antagonist antibody, in combination with Merck’s anti-PD-1 therapy,

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application (number 16/194,417) covering AllocetraTM, the Company’s immunotherapy product candidate.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to participate in 40th Annual J.P. Morgan Healthcare Conference over January 10-13, 2022.

The new omicron variant is a game changer as current vaccine producers have recognized that new SARS-CoV-2 vaccines will be necessary to combat this new threat.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of John A. Hohneker, M.D. to its Board of Directors.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to six new employees.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION).

Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.